Compare SKIL & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | NSPR |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | 2247 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 33.7M |
| IPO Year | N/A | 2009 |
| Metric | SKIL | NSPR |
|---|---|---|
| Price | $5.17 | $0.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 107.3K | ★ 128.1K |
| Earning Date | 04-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | $0.11 | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.43 | $0.63 |
| 52 Week High | $18.45 | $2.93 |
| Indicator | SKIL | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 35.77 |
| Support Level | $4.83 | $0.69 |
| Resistance Level | $8.36 | $1.04 |
| Average True Range (ATR) | 0.86 | 0.08 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 11.65 | 26.74 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.